CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：124

作者：

Maisey, NR ^{[1
]}

Norman, AR ^{[1
]}

Hill, A ^{[1
]}

Massey, A ^{[1
]}

Oates, J ^{[1
]}

Cunningham, D ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期

关键词：

pancreatic cancer; CA19-9; prognosis; chemotherapy;

D O I：

10.1038/sj.bjc.6602760

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).

引用

页码：740 / 743

页数：4

共 50 条

[21] Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
Lee, Kyong Joo
Yi, Seung Woo
Chung, Moon Jae
Park, Seung Woo
Song, Si Young
Chung, Jae Bock
Park, Jeong Youp
YONSEI MEDICAL JOURNAL, 2013, 54 (03) : 643 - 649
[22] CA19-9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy
Ma, Xiao
Zhou, Xiaohua
Guo, Jiaxuan
Feng, Xinyu
Zhao, Mengmeng
Zhang, Peng
Zhang, Chong
Gong, Shuai
Wu, Nai
Zhang, Yi
Zhang, Xiuzhong
Ren, Zeqiang
Zhang, Pengbo
BMC SURGERY, 2024, 24 (01)
[23] The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
Poruk, K. E.
Gay, D. Z.
Brown, K.
Mulvihill, J. D.
Boucher, K. M.
Scaife, C. L.
Firpo, M. A.
Mulvihill, S. J.
CURRENT MOLECULAR MEDICINE, 2013, 13 (03) : 340 - 351
[24] The Clinical Utility and Limitations of Serum Carbohydrate Antigen (CA19-9) as a Diagnostic Tool for Pancreatic Cancer and Cholangiocarcinoma
Sundeep Singh
Shou-jiang Tang
Jayaprakash Sreenarasimhaiah
Luis F. Lara
Ali Siddiqui
Digestive Diseases and Sciences, 2011, 56 : 2491 - 2496
[25] The Clinical Utility and Limitations of Serum Carbohydrate Antigen (CA19-9) as a Diagnostic Tool for Pancreatic Cancer and Cholangiocarcinoma
Singh, Sundeep
Tang, Shou-jiang
Sreenarasimhaiah, Jayaprakash
Lara, Luis F.
Siddiqui, Ali
DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (08) : 2491 - 2496
[26] The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
Engle, Dannielle D.
Tiriac, Herve
Rivera, Keith D.
Pommier, Arnaud
Whalen, Sean
Oni, Tobiloba E.
Alagesan, Brinda
Lee, Eun Jung
Yao, Melissa A.
Lucito, Matthew S.
Spielman, Benjamin
Da Silva, Brandon
Schoepfer, Christina
Wright, Kevin
Creighton, Brianna
Afinowicz, Lauren
Yu, Kenneth H.
Gruetzmann, Robert
Aust, Daniela
Gimotty, Phyllis A.
Pollard, Katherine S.
Hruban, Ralph H.
Goggins, Michael G.
Pilarsky, Christian
Park, Youngkyu
Pappin, Darryl J.
Hollingsworth, Michael A.
Tuveson, David A.
SCIENCE, 2019, 364 (6446) : 1156 - +
[27] A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer
Chen, Yuntao
Shao, Zhenyi
Chen, Wen
Xie, Hua
Wu, Zhenyu
Qin, Guoyou
Zhao, Naiqing
ONCOTARGET, 2017, 8 (18) : 29925 - 29934
[28] The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer
Mansson, Christopher
Nilsson, Anders
Urdzik, Jozef
Karlson, Britt-Marie
ANTICANCER RESEARCH, 2019, 39 (11) : 6193 - 6196
[29] CA19-9 is a significant prognostic marker of patients with stage III gastric cancer
Kambara, Yuichi
Miyake, Hideo
Nagai, Hidemasa
Yoshioka, Yuichiro
Shibata, Koji
Asai, Soichiro
Yuasa, Norihiro
EJSO, 2020, 46 (10): : 1918 - 1924
[30] Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
Wong, Derrick
Ko, Andrew H.
Hwang, Jimmy
Venook, Alan P.
Bergsland, Emily K.
Tempero, Margaret A.
PANCREAS, 2008, 37 (03) : 269 - 274

← 1 2 3 4 5 →